Cardinal Health Inc vs iShares China Large-Cap ETF — how do they compare? Cardinal Health Inc trades at $234.16 (market cap $55.88B), while iShares China Large-Cap ETF trades at $35.18. The key difference: Cardinal Health Inc pays a 0.86% dividend while iShares China Large-Cap ETF pays none, and Cardinal Health Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.
| CAH | FXI | |
|---|---|---|
Market Cap | $55.88B | — |
Sector | Health | — |
52-Week High | $240.26 | $41.75 |
52-Week Low | $146.04 | $31.59 |
Enterprise Value | $59.91B | — |
Dividend Yield | 0.86% | — |
Signals from Pluang's Aura AI — not financial advice
Cardinal Health (CAH) trades at $235.3, down 0.79% on the day, but remains near its 52-week high. The stock exhibits a bullish technical signal with consistent earnings beats in recent quarters, including Q2 2026 EPS of $2.91 versus $2.42 expected. Revenue for fiscal 2025 was $222.58 billion, with net income reaching $1.56 billion. Analyst consensus is strongly positive, with 18 buys and a $266.43 price target, reflecting confidence in the company's pharmaceutical and specialty business growth.
The outlook for CAH is favorable, driven by robust earnings performance and optimistic fiscal 2027 guidance. Key opportunities include sustained demand for specialty drugs and operational efficiency gains. Risks involve high debt levels, with a debt-to-asset ratio of 16.09 in 2025, and competitive pressures in the healthcare distribution sector. Investors should weigh strong analyst support against balance sheet leverage and market volatility.
FXI, the iShares China Large-Cap ETF, trades at $35.205, down 3.52% amid broader pressure on Chinese equities. Technical indicators show a bullish overall signal with strong moving average support, though oscillators are neutral. Recent news highlights China's export strength and AI-driven manufacturing rebound, while the ETF offers exposure to state-backed economic initiatives and upcoming dividend payments.
The outlook for FXI hinges on China's economic stabilization efforts and global demand for tech exports. Investment opportunities include diversification from US markets and exposure to AI hardware growth, but risks include US-China tensions, regulatory uncertainty, and value trap potential in Chinese equities.
Trailing returns across standard periods
Latest headlines on both assets
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.
Read more on FXI →